Space motion sickness medications - Interference with biomedical parametersThe possibility that drugs administered to Skylab 3 and 4 crewmen for space motion sickness may have interfered with their biomedical evaluation in space is investigated. The mixture of scopolamine and dextroamphetamine produced changes which allow a more valid interpretation of the early biomedical changes ocurring in weightlessness. There is no doubt that the dramatic increase in aldosterone excretion is not attributable to the drug, while the drug could have contributed to the in-flight changes observed in cortisol, epinephrine, heart rate and possibly urine volume.
Document ID
19760087414
Acquisition Source
Legacy CDMS
Document Type
Conference Paper
Authors
Vernikos-Danellis, J. (NASA Ames Research Center Moffett Field, CA, United States)
Winget, C. M. (NASA Ames Research Center Biomedical Research Div., Moffett Field, Calif., United States)
Leach, C. S. (NASA Johnson Space Center Houston, Tex., United States)
Rosenblatt, L. S. (Geneticon Oakland, Calif., United States)
Lyman, J. (NASA Ames Research Center Moffett Field, CA, United States)
Beljan, J. R. (Wright State University Dayton, Ohio, United States)